180 related articles for article (PubMed ID: 30999276)
1. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
2. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand.
Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS
Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497
[TBL] [Abstract][Full Text] [Related]
3. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS
Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700
[TBL] [Abstract][Full Text] [Related]
4. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7.
Wang R; Li JC
Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358
[TBL] [Abstract][Full Text] [Related]
5. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells.
Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS
PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619
[TBL] [Abstract][Full Text] [Related]
6. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4.
Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS
J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047
[TBL] [Abstract][Full Text] [Related]
7. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH
Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474
[TBL] [Abstract][Full Text] [Related]
8. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
9. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells.
Li LC; Jayaram S; Ganesh L; Qian L; Rotmensch J; Maker AV; Prabhakar BS
Am J Obstet Gynecol; 2011 Oct; 205(4):362.e12-25. PubMed ID: 21855847
[TBL] [Abstract][Full Text] [Related]
10. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257
[TBL] [Abstract][Full Text] [Related]
11. Knockdown of IG20 gene expression renders thyroid cancer cells susceptible to apoptosis.
Subramanian M; Pilli T; Bhattacharya P; Pacini F; Nikiforov YE; Kanteti PV; Prabhakar BS
J Clin Endocrinol Metab; 2009 Apr; 94(4):1467-71. PubMed ID: 19190106
[TBL] [Abstract][Full Text] [Related]
12. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
[TBL] [Abstract][Full Text] [Related]
13. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells.
Mulherkar N; Prasad KV; Prabhakar BS
J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102
[TBL] [Abstract][Full Text] [Related]
14. MADD is a downstream target of PTEN in triggering apoptosis.
Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS
J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283
[TBL] [Abstract][Full Text] [Related]
15. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
Yan P; Su Z; Zhang Z; Gao T
Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of Nrf2 by the combination of TRAIL and Valproic acid induces apoptotic cell death of TRAIL-resistant papillary thyroid cancer cells via suppression of Bcl-xL.
Cha HY; Lee BS; Chang JW; Park JK; Han JH; Kim YS; Shin YS; Byeon HK; Kim CH
Cancer Lett; 2016 Mar; 372(1):65-74. PubMed ID: 26721202
[TBL] [Abstract][Full Text] [Related]
17. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
[TBL] [Abstract][Full Text] [Related]
18. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment.
Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS
J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468
[TBL] [Abstract][Full Text] [Related]
19. MADD promotes the survival of human lung adenocarcinoma cells by inhibiting apoptosis.
Bi W; Wei Y; Wu J; Sun G; Guo Y; Zhang Q; Dong L
Oncol Rep; 2013 Apr; 29(4):1533-9. PubMed ID: 23443411
[TBL] [Abstract][Full Text] [Related]
20. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
